Evotec AG has entered into a medicinal chemistry collaboration with Active Biotech AB, following the successful conclusion of a High Throughput Screening campaign to identify small molecule modulators of Active Biotech’s priority biological target involved in immune disorders and cancer. Evotec will now apply its integrated medicinal chemistry platform to optimize initial screening hits with the goal of progressing into a lead optimization program. Financial details were not disclosed. Dr. Mari...